Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also involved in developing discovery-stage product candidates for inborn errors of metabolism, including maple syrup urine disease, isovaleric acidemia, and organic acidemias. It has a collaboration agreement with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; Ginkgo Bioworks to discover new living medicines to treat neurological and liver disorders. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYBX
CUSIPN/A
Phone617-401-9975
Debt
Debt-to-Equity RatioN/A
Current Ratio18.24
Quick Ratio18.24
Price-To-Earnings
Trailing P/E Ratio-1.71
Forward P/E Ratio-4.48
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.44 million
Price / Sales105.03
Cash FlowN/A
Price / CashN/A
Book Value$3.97 per share
Price / Book2.54
Profitability
EPS (Most Recent Fiscal Year)($5.88)
Net Income$-40,370,000.00
Net MarginsN/A
Return on Equity-49.62%
Return on Assets-44.73%
Miscellaneous
Employees63
Outstanding Shares25,450,000
Synlogic (NASDAQ:SYBX) Frequently Asked Questions
What is Synlogic's stock symbol?
Synlogic trades on the NASDAQ under the ticker symbol "SYBX."
When did Synlogic's stock split? How did Synlogic's stock split work?
Synlogic's stock reverse split before market open on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.
How were Synlogic's earnings last quarter?
Synlogic Inc (NASDAQ:SYBX) issued its quarterly earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.18. The biotechnology company earned $0.35 million during the quarter, compared to analysts' expectations of $0.21 million. View Synlogic's Earnings History.
When is Synlogic's next earnings date?
What price target have analysts set for SYBX?
4 analysts have issued 12 month price objectives for Synlogic's shares. Their predictions range from $15.00 to $25.00. On average, they expect Synlogic's stock price to reach $20.00 in the next twelve months. View Analyst Ratings for Synlogic.
What are Wall Street analysts saying about Synlogic stock?
Here are some recent quotes from research analysts about Synlogic stock:
- 1. HC Wainwright analysts commented, "We reiterate our Buy rating and $20 12-month target on SYBX." (6/11/2018)
- 2. According to Zacks Investment Research, "Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. " (5/22/2018)
Who are some of Synlogic's key competitors?
Some companies that are related to Synlogic include CytomX Therapeutics (CTMX), MacroGenics (MGNX), Assembly Biosciences (ASMB), Amarin (AMRN), Karyopharm Therapeutics (KPTI), OptiNose (OPTN), Kiniksa Pharmaceuticals Cl A (KNSA), Omeros (OMER), Collegium Pharmaceutical (COLL), Rocket Pharmaceuticals (RCKT), Dova Pharmaceuticals (DOVA), CymaBay Therapeutics (CBAY), ANI Pharmaceuticals Inc Common Stock (ANIP), Amphastar Pharmaceuticals (AMPH) and AMAG Pharmaceuticals (AMAG).
Who are Synlogic's key executives?
Synlogic's management team includes the folowing people:
- Dr. Peter Barrett, Exec. Chairman (Age 65)
- Dr. Aoife M. Brennan MB, BCh, BAO, MMSc, Interim Pres, CEO & Chief Medical Officer (Age 43)
- Mr. Paul Francis Miller Ph.D., Chief Scientific Officer (Age 58)
- Dr. José Carlos Gutierrez-Ramos, Advisor (Age 56)
- Prof. Timothy K. Lu, Co-Founder
Has Synlogic been receiving favorable news coverage?
News stories about SYBX stock have been trending positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Synlogic earned a coverage optimism score of 0.30 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 45.94 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Synlogic's major shareholders?
Synlogic's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (21.63%), Farallon Capital Management LLC (4.99%), Sofinnova Ventures Inc (2.94%), Artal Group S.A. (2.05%), Texas Treasury Safekeeping Trust Co. (0.53%) and Dimensional Fund Advisors LP (0.29%). Company insiders that own Synlogic stock include Jon Irvin and Paul Francis Miller. View Institutional Ownership Trends for Synlogic.
Which major investors are selling Synlogic stock?
Which major investors are buying Synlogic stock?
SYBX stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Sofinnova Ventures Inc, NEA Management Company LLC, Texas Treasury Safekeeping Trust Co., Dimensional Fund Advisors LP, JBF Capital Inc., Tibra Equities Europe Ltd and Northern Trust Corp. View Insider Buying and Selling for Synlogic.
How do I buy shares of Synlogic?
Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synlogic's stock price today?
One share of SYBX stock can currently be purchased for approximately $10.07.
How big of a company is Synlogic?
Synlogic has a market capitalization of $245.08 million and generates $2.44 million in revenue each year. The biotechnology company earns $-40,370,000.00 in net income (profit) each year or ($5.88) on an earnings per share basis. Synlogic employs 63 workers across the globe.
How can I contact Synlogic?
Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]
MarketBeat Community Rating for Synlogic (SYBX)
MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote "Outperform" if you believe SYBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
